Angelika Niebler, chair of the European Parliament committee that created the popular new European Research Council, vows to protect its political independence.
Soon it won’t be possible to fund the huge enterprises of the leading pharma companies with a handful of blockbuster drugs. The only question is whether they can change and innovate in time.
It is time to drop euphemisms like DNA medicines and gene-based medicines. Gene therapy, says Nuala Moran, has made it through to the commercial mainstream.
Politicians are great gamblers – but the EC President is playing for high stakes by wagering all on the creation of a European Institute of Technology.
Innovation policy is hot in Brussels, says Science|Business editor Richard L. Hudson. Hot enough for so a confusing array of proposals, white papers, conferences and task forces.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.